Abstract
Tyrosinemia type I (HT1) is a genetic metabolic disorder characterized by progressive liver disease, kidney disease, and rickets. The disease is caused by mutations in the FAH gene that results in deficiency of fumarylacetoacetase, an enzyme that is involved in the tyrosine degradation pathway. We investigated the clinical characteristics and molecular cause of HT1 in an affected family from Iran. Molecular analysis identified a homozygous combined missense (c.G1009G>A, p.Gly337Ser) and aberrant splicing mutation removing the first 50 nucleotides of exon 12. This mutation was only described in HT1 patients from Scandinavian countries and this is the first report from another population. Although failure to thrive is one of the typical features in HT1, our proband, similar to the reported Scandinavian patients, had normal growth and development. The results of this study have applications in patient screening and genetic counselling.
References
1. van Spronsen FJ, Smit GP, Wijburg FA, Thomasse Y, Visser G, et al. Tyrosinaemia type I: considerations of treatment strategy and experiences with risk assessment, diet and transplantation. J Inherit Metab Dis 1995;18:111–4.10.1007/BF00711742Search in Google Scholar
2. Baumann U, Preece MA, Green A, Kelly DA, McKiernan PJ. Hyperinsulinism in tyrosinaemia type I. J Inherit Metab Dis 2005;28:131–5.10.1007/s10545-005-5517-1Search in Google Scholar
3. Laberge C. Hereditary tyrosinemia in a French Canadian isolate. Am J Hum Genet 1969;21:36–45.Search in Google Scholar
4. Bergman AJ, van den Berg IE, Brink W, Poll-The BT, Ploos van Amstel JK, et al. Spectrum of mutations in the fumarylacetoacetate hydrolase gene of tyrosinemia type 1 patients in northwestern Europe and Mediterranean countries. Hum Mutat 1998;12:19–26.10.1002/(SICI)1098-1004(1998)12:1<19::AID-HUMU3>3.0.CO;2-3Search in Google Scholar
5. Tanguay RM, Valet JP, Lescault A, Duband JL, Laberge C, et al. Different molecular basis for fumarylacetoacetate hydrolase deficiency in the two clinical forms of hereditary tyrosinemia (type I). Am J Hum Genet 1990;47:308–16.Search in Google Scholar
6. Holme E, Lindstedt S. Diagnosis and management of tyrosinemia type I. Curr Opin Pediatr 1995;7:726–32.10.1097/00008480-199512000-00017Search in Google Scholar
7. Lindblad B, Lindstedt S, Steen G. On the enzymic defects in hereditary tyrosinemia. Proc Natl Acad Sci USA 1977;74:4641–5.10.1073/pnas.74.10.4641Search in Google Scholar
8. El-Shabrawi MH, Kamal NM. Current management options for tyrosinemia. Orphan Drugs: Res Rev 2013;3:1–9.10.2147/ODRR.S31501Search in Google Scholar
9. Bergeron A, D’Astous M, Timm DE, Tanguay RM. Structural and functional analysis of missense mutations in fumarylacetoacetate hydrolase, the gene deficient in hereditary tyrosinemia type 1. J Biol Chem 2001;276:15225–31.10.1074/jbc.M009341200Search in Google Scholar
10. Rootwelt H, Kristensen T, Berger R, Hoie K, Kvittingen EA. Tyrosinemia type 1–complex splicing defects and a missense mutation in the fumarylacetoacetase gene. Hum Genet 1994;94:235–9.10.1007/BF00208276Search in Google Scholar
11. Arranz JA, Pinol F, Kozak L, Perez-Cerda C, Cormand B, et al. Splicing mutations, mainly IVS6-1(G>T), account for 70% of fumarylacetoacetate hydrolase (FAH) gene alterations, including 7 novel mutations, in a survey of 29 tyrosinemia type I patients. Hum Mutat 2002;20:180–8.10.1002/humu.10084Search in Google Scholar
12. Elpeleg ON, Shaag A, Holme E, Zughayar G, Ronen S, et al. Mutation analysis of the FAH gene in Israeli patients with tyrosinemia type I. Hum Mutat 2002;19:80–1.10.1002/humu.9001Search in Google Scholar
13. Heath SK, Gray RG, McKiernan P, Au KM, Walker E, et al. Mutation screening for tyrosinaemia type I. J Inherit Metab Dis 2002;25:523–4.10.1023/A:1021275923668Search in Google Scholar
14. Rootwelt H, Hoie K, Berger R, Kvittingen EA. Fumarylacetoacetase mutations in tyrosinaemia type I. Hum Mutat 1996;7: 239–43.10.1002/(SICI)1098-1004(1996)7:3<239::AID-HUMU8>3.0.CO;2-5Search in Google Scholar
15. Forget S, Patriquin HB, Dubois J, Lafortune M, Merouani A, et al. The kidney in children with tyrosinemia: sonographic, CT and biochemical findings. Pediatr Radiol 1999;29:104–8.10.1007/s002470050551Search in Google Scholar
16. Tanguay RM, Lambert M, Grompe M, Mitchell GA. Hypertyrosinemia. In: Valle D, Beaudet AL, Vogelstein B, Kinzler KW, Antonarakis SE, et al., editors. The Online Metabolic and Molecular Bases of Inherited Disease, 2011. Available at: http://ommbid.mhmedical.com/content.aspx?bookid=474§ionid=45374064. Accessed on 1 April, 2014.Search in Google Scholar
17. Torres VE, Wang X, Qian Q, Somlo S, Harris PC, et al. Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med 2004;10:363–4.10.1038/nm1004Search in Google Scholar
18. Yamaguchi T, Pelling JC, Ramaswamy NT, Eppler JW, Wallace DP, et al. cAMP stimulates the in vitro proliferation of renal cyst epithelial cells by activating the extracellular signal-regulated kinase pathway. Kidney Int 2000;57:1460–71.10.1046/j.1523-1755.2000.00991.xSearch in Google Scholar
19. Grompe M, al-Dhalimy M. Mutations of the fumarylacetoacetate hydrolase gene in four patients with tyrosinemia, type I. Hum Mutat 1993;2:85–93.10.1002/humu.1380020205Search in Google Scholar
20. Imtiaz F, Rashed MS, Al-Mubarak B, Allam R, El-Karaksy H, et al. Identification of mutations causing hereditary tyrosinemia type I in patients of Middle Eastern origin. Mol Genet Metab 2011;104:688–90.10.1016/j.ymgme.2011.06.019Search in Google Scholar
©2014 by Walter de Gruyter Berlin/Boston
